Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; and.
Graduate School, International University of Health and Welfare, Narita, Japan.
J Cardiovasc Pharmacol. 2021 Dec 3;78(Suppl 6):S19-S29. doi: 10.1097/FJC.0000000000001089.
The endothelium plays a pivotal role in the regulation of vascular tone by synthesizing and liberating endothelium-derived relaxing factors inclusive of vasodilator prostaglandins (eg, prostacyclin), nitric oxide (NO), and endothelium-dependent hyperpolarization factors in a distinct blood vessel size-dependent manner. Large conduit arteries are predominantly regulated by NO and small resistance arteries by endothelium-dependent hyperpolarization factors. Accumulating evidence over the past few decades has demonstrated that endothelial dysfunction and coronary vasomotion abnormalities play crucial roles in the pathogenesis of various cardiovascular diseases. Structural and functional alterations of the coronary microvasculature have been coined as coronary microvascular dysfunction (CMD), which is highly prevalent and associated with adverse clinical outcomes in many clinical settings. The major mechanisms of coronary vasomotion abnormalities include enhanced coronary vasoconstrictive reactivity at epicardial and microvascular levels, impaired endothelium-dependent and endothelium-independent coronary vasodilator capacities, and elevated coronary microvascular resistance caused by structural factors. Recent experimental and clinical research has highlighted CMD as the systemic small artery disease beyond the heart, emerging modulators of vascular functions, novel insights into the pathogenesis of cardiovascular diseases associated with CMD, and potential therapeutic interventions to CMD with major clinical implications. In this article, we will summarize the current knowledge on the endothelial modulation of vascular tone and the pathogenesis of coronary macrovascular and microvascular diseases from bench to bedside, with a special emphasis placed on the mechanisms and clinical implications of CMD.
内皮在调节血管张力方面起着关键作用,通过合成和释放内皮衍生的舒张因子来调节血管张力,这些舒张因子包括血管扩张性前列腺素(如前列环素)、一氧化氮(NO)和内皮依赖性超极化因子,以一种特定的血管大小依赖性方式。大的管道动脉主要受 NO 调节,小的阻力动脉受内皮依赖性超极化因子调节。过去几十年的大量证据表明,内皮功能障碍和冠状动脉舒缩运动异常在各种心血管疾病的发病机制中起着至关重要的作用。冠状动脉微血管的结构和功能改变被称为冠状动脉微血管功能障碍(CMD),在许多临床情况下,CMD 非常普遍,并与不良的临床结局相关。冠状动脉舒缩运动异常的主要机制包括心外膜和微血管水平的冠状动脉收缩反应性增强、内皮依赖性和非内皮依赖性冠状动脉舒张能力受损,以及结构因素引起的冠状动脉微血管阻力升高。最近的实验和临床研究强调了 CMD 是心脏以外的系统性小动脉疾病,是血管功能的新兴调节剂,为与 CMD 相关的心血管疾病的发病机制提供了新的见解,以及对 CMD 的潜在治疗干预措施,具有重要的临床意义。在本文中,我们将总结从基础到临床内皮调节血管张力和冠状动脉大血管和微血管疾病发病机制的最新知识,特别强调 CMD 的机制和临床意义。